Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 4/20 | 0.41 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.41 |
| ▸ | ESRRB | O95718 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5313978 | 0.81 | TRPV1 (0.45) | — | |
| SCHEMBL6381994 | 0.80 | TSHR (0.52) | RECQLKCNH2TP53TSHRSIGMAR1 | |
| SCHEMBL1660004 | 0.78 | GRIA4 (0.47) | RECQLKCNH2GRIA4ESRRGSLC13A5 | |
| SCHEMBL6990008 | 0.78 | GRIA4 (0.44) | RECQLKCNH2GRIA4ESRRGSLC13A5 | |
| SCHEMBL29182459 | 0.78 | TAAR1 (0.46) | TP53TSHRGPR84 | |
| SCHEMBL8648913 | 0.78 | ALDH1A1 (0.36) | RECQLKCNH2 | |
| SCHEMBL697688 | 0.77 | CA2 (0.52) | KCNH2GRIA4ESRRGSLC13A5ESRRB | |
| SCHEMBL115558 | 0.77 | KCNH2 (0.49) | RECQLKCNH2GRIA4ESRRGSLC13A5 | |
| SCHEMBL7456580 | 0.76 | KCNH2 (0.59) | KCNH2GRIA4ESRRGSLC13A5ESRRB | |
| SCHEMBL17193503 | 0.76 | LPL (0.45) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007047575-A2 | PHARMACOLOGICAL TREATMENTS FOR SLEEP-RELATED BREATHING DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-26 | — | — | WO | disclosed |
| US-6872748-B2 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | DIGITAL BIOTECH CO., LTD. (KR) | 2005-03-29 | — | — | US | disclosed |
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | MEDIFRON DBT CO., LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | TRPV1, OPRL1, GPR180 | RECQL 2307/4885KCNH2 490/4885GRIA4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.